the comparative health outcomes in immune- mediated ... · shilpa venkatachalam, phd: i can confirm...

27
The Comparative Health Outcomes in Immune- Mediated Diseases Collaborative (CHOICE) Study Jeffrey Curtis, MD, MS, MPH Professor of Medicine @RADoctor Shilpa Venkatachalam, PhD Associate Director, Patient- Centered Research GHLF

Upload: others

Post on 22-Jun-2020

1 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

The Comparative Health Outcomes in Immune-Mediated Diseases Collaborative (CHOICE) Study

Jeffrey Curtis, MD, MS, MPHProfessor of Medicine

@RADoctor

Shilpa Venkatachalam, PhDAssociate Director, Patient- Centered Research GHLF

Page 2: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

Jeffrey Curtis, MD, MS, MPH: Consulting fees and contracted research with AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Eli Lily, Janssen, Maraid, Phizer, Regeneron, Roche, and UCB.

Shilpa Venkatachalam, PhD:I can confirm that I do not receive any direct funds from industry related to RA, nor do I in any capacity bear relationship with industry, including pharmaceutical companies related to RA that may pose as a conflict of interest in my capacity researcher for the CHOICE study. I am currently employed by the Global Healthy Living Foundation as the Associate Director, Patient Centered Research. GHLF receives grants and sponsorships from pharmaceutical manufacturers as well as other private foundations. A full list of GHLF funders is publicly available here: https://www.ghlf.org/our-partners/ None of these partners, however, have the potential to bias or appear to bias my involvement in this project. Any possible conflict of interest that might arise will be reported promptly by GHLF.

Page 3: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

Researcher Perspective: CHOICE Study

Page 4: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

Background: Need to make challenging decisions amongst a variety of treatment options for autoimmune and inflammatory conditions given widely variable safety profiles; limited data on medication effectiveness from patients’ perspective

Aim 1: Safety of immunomodulatory medications (e.g. biologics), researcher perspective

Aim 2: Comparative effectiveness of immunomodulatory medications, patient perspective

Data infrastructure EHR data from 3 CDRNs Patient data from 5 PPRNs Health plan claims

Recruitment (Aim 2 Sub-AIM) CDRNs recruit patients to PPRNs PPRNs recruit patients to Study

Page 5: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

Example of variability in CDM data provided

• Low percent = GOOD

• Includes zero refills for autoimmune prescription refills

Page 6: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

Variability in Sidecar Data provided

Page 7: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

AIM 1 Safety Results from CDRN Sites

Def 0) no requirement for any prior data; Def 1) >6 months (m) from first medical inpatient or outpatient medical encounter of any type; Def 2) >6m from first prescription [Rx] for any medication; Def 3) >6m from first medical encounter for disease indication (e.g. RA, vasculitis); Def 4) >6 m from first prescription for any disease-specific rheumatologic therapy

Page 8: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

AIM 1 Data that could

be linked to CMS Data

Total patient data received from CDRNsN = 183,372

Patients with some autoimmune diseaseN= 170,032

Patients with RA, PsA, PSO, IBD, AS, Vasculitis or JIA diagnosis codeN = 173,545

Patients with any medication information (including parenteral medications) N = 140,838

Patients with any RA, PsA, PSO, IBD, AS, Vasculitis or JIA medicationsN = 63,885

Patients classified as having RA, PsA, PSO, IBD, AS, Vasculitis or JIA after using a Rx/Px for these diseases, but no additional drugs for these diseases afterward

N = 31,878

After excluding for HIV/Cancer/SLE/Organ Transplant/autoimmune diagnosis before 6 monthsN = 37,453

After excluding for vasculitis (except for the vasculitis cohort)N = 37,393

Patients linked to CMS data N = 1,956

Page 9: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

ArthritisPower patients (AIM 2) who could be linked to CMS data

5,637 Patients with Medicare (Medicare advantage)

5,559 Patients with date of birth (DOB)

5,545 Patients with sex

5,544 Patients with zip code

2,352 Patients uniquely linked based on DOB, sex and zip code

Page 10: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

AIM 2 Patient Reported Outcomes (PROs)Example from PARTNERS data analyses

Aimed to compare baseline PROs to 6 months after newly starting a medication for treatment of JIA

Inclusion criteria:• PRO measured with 30 days prior or 7 days after newly starting

medication (methotrexate or biologic)• Subsequent PRO measured between 3 and 8 months after newly

starting medication

Outcome:• PROMIS measures of Pain interference, Physical function, Fatigue• Patient/Parent Global Assessment of Disease Activity• If newly started medication was discontinued prior to 6 month PRO

measurement, then most recent score (including baseline score) was assessed.

Page 11: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

Important Differences in Baseline Characteristics

MTX monotherapy

TNFi monotherapy

MTX+TNFi combination

% RF+ Polyarthritis 12% 10% 25%

% Spondyloarthritis 18% 50% 23%

Mean disease duration (days)

222 580 110

% High disease activity 78% 79% 87%

Initial analyses show that high disease activity is strongly associated with subsequent improvement in PROs.

Page 12: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

Changes in PROMIS Pain Interference

MTX MONOTHERAPY

TNFIMONOTHERAPY

MTX+TNFICOMBINATION

Number of patients 176 42 40

Baseline Score Mean/Median

55.41 / 55.70 57.05 / 58.00 57.95 / 59.00

Mean Delta -4.11 -2.75 -7.51

Median Delta -2.70 -0.50 -5.75

Page 13: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

Changes in PROMIS Physical Function

MTX monotherapy TNFi monotherapy MTX+TNFi combination

Number of patients 193 31 39

Baseline Score Mean/Median

39.21 / 37.90 37.78 / 36.90 35.27 / 34.20

Mean Delta +7.37 +6.69 +10.20

Median Delta +6.00 +4.90 +6.90

Page 14: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

PARTNERS AIM 2 Summary to Date

• Clinically relevant improvements in PROs were observed following initiation of new medications

• There appear to be differences in improvement across different medication choices, but important baseline differences in patients’ characteristics (especially disease activity and possibly disease phenotype) necessitate adjusted analyses

Page 15: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

Administratively

• SMART IRB functionality was limited

• Variability in SMART IRB capacity among CDRN/PPRN sites

• Local IRB approvals still required by sites even when using SMART IRB

• Template DUA not accepted “as is” for all sites; changes requested AFTER execution

• Uncertainties about DUA permissions to share LDS (vs. de-identified)

• Contractual processes and governance structures varied by CDRN and by individual site

• Contractual/IRB dependencies – i.e. Human subjects protocol cannot be submitted to IRB without contract number, but contract cannot be routed without IRB approval; DUA requires IRB approval

Page 16: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

AIM 1• Should involve ALL possible stakeholders early in the process (i.e. statisticians/programmers

were not oriented to the protocol when it was time to extract the data)

• Variability in CDRN data that was available (both CMD and sidecar)• CDRNs had varying levels of standardization to the CDM, with some having no

centralization. • Missing 45-100 % of refill data on autoimmune diseases.• Mother-baby linkage data was not available at four of the five data marts because (1)

IRB nightmare to get baby IDs, (2) there was a limited number of female RA patients of child-bearing age who had babies at the data mart and (3) it was just not available.

• PCORnet CDM was inadequate for representation of the data• QA/QC was difficult between CDM versions (data was extracted by the data marts, but

while waiting for DUA execution, the data marts updated their CDM versions)

• Necessary to have a physician champion at each data mart

Page 17: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

AIM 2• No harmonization in PRO data collection, frequency and method of collection by PPRNs• Variability in flexibility of PPRNs to modify existing PRO collection versus using concurrently

collected data for other studies• Establishing the baseline anchor not possible in all PPRNs - Added two additional outcomes

to compensate• Standardized CDRN to PPRN recruitment letters proved an impossibility • Variability in CDRN recruitment capacity

• One data mart’s patient portal team requested changes to the vetted and IRB approved recruitment letters requiring a 4-month delay

• One data mart waited 3.5 months for IRB approval related to messaging patients through the patient portal

• One data mart lacked the capacity and had to build the infrastructure• One data mart was unable to engage in active messaging (could use passive messaging)

• PPRNs were split over whether to invite members to JOIN the CHOICE study vs. ask them to provide more (or regular) data without actually joining the study

Page 18: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

Stakeholder Perspective

Page 19: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

What do we mean by stakeholder (patient) perspective? Patients are the only ones who can tell researchers how well or not well a treatment works for them, how to best contact them, and how often they want to provide data.

Why include patients? • Patient Reported Outcomes (PROs) can only come

from patients. • This data, from thousands of patients, is then turned

into information that physicians and other patients use to make decisions about treatments.

• But, how can researchers feasibly connect with and engage thousands of patients

Page 20: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

Patient Powered Research Networks (PPRNs)

Page 21: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

User opens app and is prompted through a ‘wizard-like’ process to participate in a study via a walk-through tailored to their cohort providing an enhanced user experience.

Page 22: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

How were patient stakeholders engaged?

Regular (e.g. monthly) patient governor meetings that included updates and feedback on the CHOICE Study

Guidance on which PROs were most important to patients (fatigue, pain interference, physician function – not IBD, social participation – DSA)Recruitment materials: creating and vetting the recruitment letters and messaging

Frequency of data collection: once to twice a month for 3-6 months

Reducing attrition - compensation (?) and, if yes, what type and how much

Sustaining engagement for continued participation in longitudinal studies

Page 23: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

Autoimmune and Systemic Inflammatory Syndromes Collaborative Research Group (ASIS CRG) PPRN Representation

Autoimmune ArthritisPower (ARthritis patient Partnership with

comparative Effectiveness Researchers) – Adult

rheumatology

CCFA Partners (Crohn’s & colitis foundation of America) – Adult IBD

PARTNERS (Patients, Advocates and

Rheumatology Teams Network for Research and

Service) – Childhood rheumatology

ICN (ImproveCareNow: A Learning Health System for

Children with Crohn’s Disease and Ulcerative

Colitis) – Child IBD

V-PPRN (Vasculitis Patient Powered Research Network)

MS –PPRN (Multiple Sclerosis Patient-Powered

Research Network)

Page 24: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

Engaging with patient

participants

• Education in-app and via CreakyJointswebsite and social media platforms

• Engagement webinars on current research studies and other topics of interest to patients – CHOICE Webinar

• Frequent email contact• Monthly reminders to complete PROs

and medication data• Quarterly newsletter• Announcements of special events and

milestones• Annual summary of participation• Webinar alerts

Page 25: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

Learn More

• www.pcori.org

[email protected]

• #PCORI2019

• Arthritispower.org

Page 26: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

Questions?

Page 27: The Comparative Health Outcomes in Immune- Mediated ... · Shilpa Venkatachalam, PhD: I can confirm that I do not receive any direct funds from industry related to RA, nor do I in

Thank You!Jeffrey Curtis, MD, MS, MPHProfessor of Medicine

@RADoctor

Shilpa Venkatachalam, PhDAssociate Director, Patient-Centered Research GHLF